GLP-1 receptor agonists may mediate cardioprotection by improving vascular regenerative progenitor cell flux and mitigating hallmarks of vascular aging in cardiometabolic diseases.
This review highlights a novel cardioprotective mechanism of GLP-1RAs involving the prevention of vascular aging through the modulation of stem cell exhaustion, intercellular communication, and chronic inflammation.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of type 2 diabetes and obesity. Due to class-wide reduction in major adverse cardiovascular events in cardiovascular outcome trials and pleiotropic actions in multiple tissues, the use of GLP-1RAs has expanded beyond metabolic diseases. Recent studies have reported GLP-1RA efficacy for the treatment of atherosclerosis, heart failure and peripheral artery disease, alongside evolving potential in chronic kidney disease. The recent discovery that GLP-1RAs can improve vascular regenerative progenitor cell flux during type 2 diabetes has uncovered a novel mechanism implicating 3 classical hallmarks of vascular aging: (1) stem cell exhaustion, (2) altered intercellular communication, and (3) chronic systemic inflammation. In this review we discuss recent evidence demonstrating that imbalances in hematopoiesis during cardiometabolic diseases intersect with the senescence-associated secretory phenotype to elevate chronic inflammation and accelerate vascular aging. With a focus on stem cells as the master regulators of regenerative processes, we integrate the activities of GLP-1RAs that shift the balance from damage accumulation to repair competence in blood vessels prematurely aged by cardiometabolic syndrome.
This Circulation Research review proposes a new mechanism for the cardiovascular benefits of GLP-1 RAs, suggesting they prevent vascular aging, a topic of intense interest in preventive cardiology.
Dennis et al. (Thu,) conducted a review in Type 2 diabetes, obesity, and cardiometabolic diseases. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) was evaluated. GLP-1 receptor agonists may mediate cardioprotection by improving vascular regenerative progenitor cell flux and mitigating hallmarks of vascular aging in cardiometabolic diseases.